Effects of a specific endothelin-converting enzyme inhibitor on cardiac, renal, and neurohumoral functions in congestive heart failure: Comparison of effects with those of endothelin A receptor antagonism

Circulation

Volumn 99, Issue 4, 1999, Pages 570-577

  Wada, Atsuyuki ^a   Tsutamoto, Takayoshi ^a   Ohnishi, Masato ^a   Sawaki, Masahide ^a   Fukai, Daisuke ^a   Maeda, Yukiharu ^a   Kinoshita, Masahiko ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Endothelin; Enzymes; Heart failure; Hormones; Receptors

Indexed keywords

2 [[2 [[2 [[(HEXAHYDRO 1H AZEPIN 1 YL)CARBONYL]AMINO] 4 METHYLPENTANOYL]AMINO] 3 (1 METHYL 1H INDOL 3 YL)PROPIONYL]AMINO] 3 (2 PYRIDYL)PROPIONIC ACID; 5,6,8,13 TETRAHYDRO 1,6,9,14 TETRAHYDROXY 3 (2 HYDROXYPROPYL) 7 METHOXY 8,13 DIOXOBENZO[A]NAPHTHACENE 2 CARBOXYLIC ACID; ALDOSTERONE; ANGIOTENSIN; ATRIAL NATRIURETIC FACTOR; BIG ENDOTHELIN 1; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN CONVERTING ENZYME INHIBITOR; NEUROHORMONE; RENIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEPRESSOR RESPONSE; DIURESIS; DOG; DRUG EFFECT; ENDOCRINE FUNCTION; FEMALE; GLOMERULUS FILTRATION RATE; HEART FUNCTION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION; KIDNEY PLASMA FLOW; LUNG CAPILLARY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; NATRIURESIS; NONHUMAN; PRIORITY JOURNAL; SYSTEMIC VASCULAR RESISTANCE;

EID: 0033514321     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.4.570     Document Type: Article

References (29)

1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332: 411-415.
2. Xu D, Emoto N, Giaid A, Slaughter C, Kaw S, de Wit D, Yanagisawa M. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell. 1994;78:473-485.
3. Tsutamoto T, Wada A, Maeda Y, Adachi T, Kinoshita M. Relationship between endothelin-1 spillover in the lungs and the pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol. 1994;23:1427-1433.
4. Pacher R, Stanek B, Hülsmann M, Koller-Strametz J, Berger R, Schuller M, Hartter E, Ogris E, Frey B, Heinz G, Maurer G. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. Am J Coll Cardiol. 1996;27: 633-641.
5. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature. 1996;384:353-355.
6. Mulder P, Richard V, Derumeaux G, Hogie M, Henry JP, Lallemand F, Compagnon P, Macè B, Comoy E, Letac B, Thuillez C. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation. 1997;96:1976-1982.
7. Seo B, Oemar BS, Siebenmann R, Segesser LV, Lüscher TF. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation. 1994;89:1203-1208.
8. Love MP, Haynes WG, Gray GA, Webb DJ, McMurray JJ. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation. 1996;94:2131-2137.
9. Wada A, Tsutamoto T, Fukai D, Ohnishi M, Maeda K, Hisanaga T, Maeda Y, Matsuda Y, Kinoshita M. Comparison of the effects of selective endothelin ETA and ETB receptor antagonists in congestive heart failure. J Am Coll Cardiol. 1997;30:1385-1392.
10. Tsurumi Y, Fujie K, Nishikawa M, Kiyoto S, Okuhara M. Biological and pharmacological properties of highly selective new endothelin converting enzyme inhibitor WS79089B isolated from Streptosporangium roseum No. 79089. J Antibiotics 1995;48:169-174.
11. Tsurumi Y, Ohhata N, Iwamoto Y, Shigematsu N, Sakamoto K, Nishikawa M, Kiyoto S, Okuhara S. WS79089A, B and C, new endothelin converting enzyme inhibitors isolated from Streptosporangium roseum. No. 79089. J Antibiotics. 1994;47:619-630.
12. Wada A, Tsutamoto T, Matsuda Y, Kinoshita M. Cardiorenal and neurohumoral effects of endogenous atrial natriuretic peptides in dogs with severe congestive heart failure using a specific antagonist for guanylate cyclase coupled receptor. Circulation. 1994;89:2232-2240.
13. Emoto N, Yanagisawa M. Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. J Biol Chem. 1995;270:15262-15268.
14. Wada A, Tsutamoto T, Maeda Y, Kanamori T, Matsuda Y, Kinoshita M. Endogenous atrial natriuretic peptide inhibits endothelin-1 secretion in dogs with severe congestive heart failure. Am J Physiol. 1996;270: H1819-H1824.
15. Kanamori T, Wada A, Tsutamoto T, Kinoshita M. Possible regulation of renin release by ANP in dogs with heart failure. Am J Physiol. 1995;268: H2281-H2287.
16. Tsutamoto T, Bito K, Kinoshita M. Plasma atrial natriuretic polypeptide as an index of left ventricular end-diastolic pressure in patients with chronic left-sided heart failure. Am Heart J. 1989;117:599-606.
17. Löffler B-M, Roux S, Kalina B, Clozel M, Clozel J-P. Influence of congestive heart failure on endothelin levels and receptors in rabbits. J Mol Cell Cardiol. 1993;25:407-416.
18. Kobayashi T, Miyauchi T, Sakai S, Maeda S, Yamaguchi I, Goto K, Sugishita Y. Down-regulation of ETB receptor, but not ETA receptor, in congestive lung secondary to heart failure: are marked increases in circulating endothelin-1 partly attributable to decrease in lung ETB receptor-mediated clearance of endothelin-1? Life Sci. 1998;62:185-193.
19. Kirshbom PM, Tsui SS, DiBernardo LR, Meliones JN, Schwinn DA, Ungerleider RM, Gaynor JW. Blockade of endothelin-converting enzyme reduces pulmonary hypertension after cardiopulmonary bypass and circulatory arrest. Surgery. 1995;118:440-445.
20. Thomas PB, Liu ECK, Webb ML, Mukherjee R, Hebbar L, Spinale FG. Exogenous effects and endogenous production of endothelin in cardiac myocytes: potential significance in heart failure. Am J Physiol. 1996;271: H2629-H2637.
21. Spinale FG, Walker JD, Mukherjee R, Iannini JP, Keever AT, Gallagher KP. Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits: beneficial effects on left ventricular and myocyte function. Circulation. 1997; 95:1918-1929.
22. Moe O, Tejedor A, Campbell WB, Alpern RJ, Henrich WL. Effects of endothelin on in vitro renin secretion. Am J Physiol. 1991;260:E521-E525.
23. Kawaguchi H, Sawa H, Yasuda H. Endothelin stimulates angiotensin I to angiotensin II conversion in cultured pulmonary artery endothelial cells. J Mol Cell Cardiol. 1990;22:839-842.
24. Belloni AS, Rossi GP, Andreis PG, Neri G, Albertin G, Pessina AC, Nussforfer GG. Endothelin adrenocortical secretagogue effect is mediated by the B receptor in rats. Hypertension. 1996;27:1153-1159.
25. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, Ohnishi M, Sugimoto Y, Kinoshita M. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation. 1997;96:509-516.
26. King AJ, Brenner BM, Anderson S. Endothelin: a potent renal and systemic vasoconstrictor peptide. Am J Physiol. 1989;256: F1051-F1058.
27. Bird JE, Webb ML, Wasserman AJ, Liu ECK, Giancarli MR, Durham SK. Comparison of a novel ETA receptor antagonist and phosphoramidon in renal ischemia. Pharmacology. 1995;50:9-23.
28. Levens NR, Peach MJ, Carey RM. Role of the intrarenal renin-angiotensin system in the control of renal function. Circ Res. 1981;48: 157-167.
29. Travill C, Williams T, Pate P, Song G, Chalmers J, Lightman S, Sutton R, Noble M. Haemodynamic and neurohumoral response in heart failure produced by rapid ventricular pacing. Cardiovasc Res. 1992; 26:783-790.